Affordability of Health Goods & Services

d. Overhead cost

Ongoing expense of operating a business that cannot be conveniently traced to any particular cost unit: a. Acquisition cost b. Compounding fee c. Prevailing price d. Overhead cost

c. Health Technology Assessment Unit

The DOH office responsible for the review of the medicines to be included in the Primary Care Formulary: a. Health Facility Development Bureau b. Pharmaceutical Division c. Health Technology Assessment Unit d. Centers for Health Development

d. Food and Drug Administration

The agency responsible to investigate alleged violations of Maximum Retail/Wholesale Price of drugs and medicines in accordance with relevant laws: a. PhilHealth b. Department of Health c. Department of Trade and Industry d. Food and Drug Administration

f. Only B, C, and D are correct.

The countries used as the basis for external reference pricing in determining the maximum retail price of drugs and medicines: a. United States of America b. United Kingdom c. Canada d. Australia e. All of the above are correct. f. Only B, C, and D are correct.

d. FDA

The following agencies must have representatives as members of the Price Negotiation Board, EXCEPT: a. PhilHealth b. Department of Trade and Industry c. DOH d. FDA

d. All of the above are correct.

The following are the benefits of centralized price negotiation thru the Price Negotiation Board: a. Promote transparency in price setting for health commodities b. Improve efficiency in government spending on health commodities c. Guarantee access to affordable and quality health commodities d. All of the above are correct. e. Only A and B are correct.

d. Low price differential from other countries

The following are the criteria being used by the Drug Price Advisory Board for selecting drugs and medicines for consideration under maximum retail pricing, EXCEPT: a. Patient groups and medical societies recommendations b. Limited competition c. Highest disease burden d. Low price differential from other countries

d. All of the above are correct.

A re-negotiation may be conducted as deemed appropriate by the end-user before the expiration of the Memorandum of Agreement based on a set of criteria that includes the following: a. New price has been observed in other countries. b. New price has been submitted to the end-user by the company. c. Updated epidemiologic report or relevant real-world evidence data is available. d. All of the above are correct. e. Only A and B are correct.

e. Only A and C are correct.

As provided in the UHC Act, drugs and medicines listed in the Primary Care Formulary (PCF) shall have fairly priced generic equivalents. The formulation of the PCF shall be based on: a. Common morbidities and mortalities in the locality b. Prevailing disease patterns in the country c. Local needs d. All of the above are correct. e. Only A and C are correct.

b. Drug Price Watch

Consumer's guide that provides information on where to get the cheapest medicines within their area: a. Electronic Drug Price Monitoring System b. Drug Price Watch c. Philippine National Formulary d. Primary Care Formulary

b. Patented health commodity

Drug or medical device that has been granted intellectual property rights, which provides a legal right to exclude others from making, using, selling, and importing for a limited period of years: a. Proprietary health commodity b. Patented health commodity c. Single-sourced health commodity d. Innovative health commodity

d. Proprietary health commodity

Drug or medical device that is used, produced, or marketed under exclusive legal right and protected by patent: a. Innovative health commodity b. Patented health commodity c. Single-sourced health commodity d. Proprietary health commodity

c. Comparator drug

Drug or medicine with an active pharmaceutical ingredient or molecule that was first originally marketed globally: a. Branded medicine b. Generic drug c. Comparator drug d. Controlled medicine

a. Submission of quarterly price monitoring reports to the Secretary of Health

In the implementation of Maximum Retail Price (MRP), the Department of Trade and Industry is responsible for: a. Submission of quarterly price monitoring reports to the Secretary of Health b. Monitoring both suppliers and drug outlets on their compliance to MRP c. Investigation of alleged violations of MRP d. Dissemination of Information, Education and Communication materials related to the imposition of MRP

a. DOH Pharmaceutical Division

In the implementation of price mark-ups in DOH-owned health facilities, the following is responsible to endorse to the Commission on Audit any report of non-compliance observed by the Internal Audit Service: a. DOH Pharmaceutical Division b. DOH Hospitals c. Drug Price Advisory Committee d. Regional Drug Price Monitoring Office e. All of the above are correct.

d. All of the above are correct.

The following are the objectives of the Administrative Order 2020-0043 (Guidelines on Ensuring the Affordability of Essential Medicines in DOH Facilities Through the Regulation of Price Mark-ups): a. Provide mechanisms for setting the allowable mark-ups on essential medicines being dispensed or charged to the patients and to PhilHealth in all DOH hospitals b. Provide guidelines for the enforcement, implementation, and monitoring of the mark-up scheme across all DOH facilities nationwide c. Alignment of the policy in the implementation of the Universal Health Care which mandates the prescribing of uniform rules and structures in setting mark-ups for drugs and medical devices and supplies d. All of the above are correct. e. Only A and B are correct.

e. Only B and C are correct.

The following are true in the imposition of maximum retail price (MRP) on drugs and medicines: a. MRP is applicable to a specific brand and strength and form of drugs and medicines. b. Special discounts are still honored for drugs and medicines with MRP. c. MRP is VAT exempted. d. All of the above are correct. e. Only B and C are correct.

d. All of the above are correct.

The following are true regarding generic alternatives of drugs and medicines: a. Similar active ingredients as the branded medicines b. Proven safe, effective, and of the same quality as branded medicines c. Cheaper than branded medicines d. All of the above are correct. e. Only B and C are correct.

d. Price Negotiation Board Technical Working Group

The following is responsible to synthesize the data submitted by the end-user and Health Technology Assessment Council: a. Price Negotiation Board Secretariat b. Price Negotiation Board c. DOH Pharmaceutical Division d. Price Negotiation Board Technical Working Group

f. Both B and C are correct.

The following prerequisites and preparation apply for health commodities that are already listed in the Philippine National Formulary: a. The Health Technology Assessment Council (HTAC) may nominate these drugs and vaccines. b. End-users may nominate these drugs and vaccines. c. The Price Negotiation Board Secretariat must issue a Letter of Intent to the companies to submit a price offer or proposal. d. The HTAC Secretariat must submit the list of health commodities recommended for price negotiation. e. Both A and D are correct. f. Both B and C are correct.

b. Companies are given fifteen (15) working days upon receipt of the decision of the Board to submit an appeal.

The following statements are correct for successful outcomes of price negotiation, EXCEPT: a. Negotiated prices are only valid for one (1) year except when there is a Multi-Year Obligational Authority. b. Companies are given fifteen (15) working days upon receipt of the decision of the Board to submit an appeal. c. A Memorandum of Agreement shall be executed for drugs and vaccines listed in the Philippine National Formulary. d. The final agreed price must be made publicly available.

a. Random monitoring of medicines prices shall be done regularly at DOH-owned facilities by the FDA.

The following statements are correct regarding price mark-ups of drugs and medicines in DOH-owned health facilities, EXCEPT: a. Random monitoring of medicines prices shall be done regularly at DOH-owned facilities by the FDA. b. The government has the right to issue a price freeze or suggested retail prices during public health emergencies. c. The prevailing mark-up rate of medicines of the same brand should be followed during Emergency Procurement. d. The level of mark-up should remain the same regardless of the quantity supplied by the hospital pharmacies.

e. Only A and C are correct.

The following statements are correct regarding the computation of retail prices for highly specialized drugs: a. Mark-up price is computed similar to the regular essential medicines with an additional compounding fee. b. A fixed-rate compounding fee is added on top of the mark-up. c. No compounding fee is added for highly specialized drugs availed by outpatients. d. All of the above are correct. e. Only A and C are correct.

a. The decision of the Head of DOH HRT shall be final and executory.

The following statements are true regarding the appeal of any health facility whose license or accreditation is revoked or suspended due to noncompliance to the provisions of Administrative Order 2021-008 on public access to price information of all health goods and services, EXCEPT: a. The decision of the Head of DOH HRT shall be final and executory. b. All pertinent documents and records of the applicant shall be elevated by the Health Facility and Services Regulatory Bureau or Center for Health Development to the HRT. c. The notice of appeal shall be filed to the Head of the DOH Health Regulation Team (HRT) d. A notice of appeal shall be filed within ten (10) days upon receipt of the notice of the decision.

c. The council members shall elect the chairperson.

The following statements are true regarding the composition of the Drug Price Advisory Board, EXCEPT: a. The number of council members shall be odd. b. There shall be a public health and an epidemiology expert as members of the council. c. The council members shall elect the chairperson. d. The members of the council are co-terminus with the Secretary of Health.

e. Only A and B are correct.

The following statements are true regarding the guidelines on public access to price information of all health goods and services in DOH-owned health facilities: a. Health facilities must ensure that an updated price list is accessible to the public and patients at all times. b. The price list must be itemized comprehensively. c. The Department of Trade and Industry shall monitor the compliance of health facilities to the price list. d. All of the above are correct. e. Only A and B are correct.

b. The prices and fees must be presented in a fixed amount.

The following strategies are aimed to make price information of all health goods and services available and accessible, EXCEPT: a. The price list must be in a conspicuous area of the health facility. b. The prices and fees must be presented in a fixed amount. c. The price list must be posted on the facility's website. d. The Price list must be updated and part of the requirements for licensing and accreditation.

c. Drug Price Advisory Council

The independent technical body duly authorized and delegated by the Secretary of Health to provide technical advice and guidance to the DOH in implementing appropriate measures that promote and ensure access to affordable quality drugs and medicines for all consumers in the Philippines: a. Price Negotiation Board b. Health Technology Assessment Council c. Drug Price Advisory Council d. Public Health Ethics Committee

e. All of the above are correct.

The prices of the following shall be included in the list of price information in all DOH-owned health facilities: a. Type of accommodation b. Medical and Surgical Procedures c. Professional Fees d. Drugs, medicines, and medical supplies e. All of the above are correct. f. Only A, B, and D are correct.

c. Acquisition cost

Unit cost reflected in the Purchase Order which is the basis in the computation of price mark-ups: a. Prevailing price b. Compounding fee c. Acquisition cost d. Overhead cost